Imjudo

Tremelimumab, the active ingredient in Imjudo, is a CTLA‑4 inhibitor presented as an intravenous formulation for infusion use. It is employed in oncology to enhance T‑cell mediated immune responses against certain advanced solid tumours. The drug is indicated for patients with unresectable or metastatic disease where standard therapies have limited efficacy.

GNH USA supplies Imjudo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products.

Imjudo is a CTLA‑4 checkpoint inhibitor used in the treatment of specific solid tumours and in clinical investigation of other cancers. - Malignant mesothelioma: improves overall survival when combined with durvalumab in patients with unresectable disease. - Advanced non‑small cell lung cancer (investigational): being evaluated for efficacy in combination regimens. - Metastatic melanoma (investigational): studied as part of checkpoint‑inhibitor combination therapies.

Common Side Effects: - Fatigue: mild to moderate tiredness experienced during treatment. - Rash: skin erythema or maculopapular eruptions. - Diarrhea: loose stools, sometimes watery. - Nausea: feeling of sickness, occasional vomiting. - Infusion‑related reactions: flushing, chills, or mild hypotension during administration. - Pruritus: itching of the skin.

Serious or Rare Side Effects: - Immune‑mediated colitis: severe inflammation of the colon requiring prompt treatment. - Hepatitis: liver inflammation with elevated enzymes. - Endocrinopathies: thyroiditis, hypophysitis, or adrenal insufficiency. - Pneumonitis: inflammation of lung tissue, potentially life‑threatening. - Severe infusion reactions: anaphylaxis or cytokine release syndrome. - Myocarditis: inflammation of heart muscle, rare but critical.

Before initiating therapy, clinicians should evaluate patient history and monitor for immune‑related events. - Monitor immune‑related adverse events: perform regular assessments of organ function and symptom review. - Assess pre‑existing autoimmune disease: weigh risk versus benefit and consider close monitoring. - Screen for infections: test for latent tuberculosis, hepatitis B/C, and HIV before treatment. - Avoid concurrent high‑dose immunosuppressants unless medically required: they may diminish therapeutic effect. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tremelimumab may interact with other agents that modify immune function. Major Interactions (Avoid): - Concurrent use with other immune checkpoint inhibitors: heightened risk of severe immune toxicity. - Live vaccines: contraindicated due to potential for uncontrolled infection. - High‑dose systemic steroids or other strong immunosuppressants: may reduce antitumor efficacy. Moderate Interactions (Monitor Closely): - CYP450 substrate drugs: monitor levels as immune modulation can affect metabolism. - Anticoagulants: observe for bleeding if severe infusion reactions cause thrombocytopenia. - Non‑live vaccines: efficacy may be reduced; assess immune response.